Convalescent Plasma as Potential Therapy for Severe COVID-19 Pneumonia
Convalescent Plasma as Potential Therapy for Severe COVID-19 Pneumonia
To determinate feasibility, safety and outcome with convalescent plasma in patients with
 severe COVID-19 penumonia
COVID-19 convalescent plasma will be infused to patients with severe COVID-19 pneumonia to
 determine feasibility, safety and clinical outcome efficacy by survival at-28 days. Data will
 be compared with match control arm patients without plasma infusion
Inclusion Criteria:

 -  Adult patients ≥18, and non-pregnant women

 -  Severe or critical COVID-19 disease define by one or more of the following: blood
 oxygen saturation ≤ 94% on supplemental oxygen by nasal cannula at least 3 L/min,
 non-rebreathing mask (NRO2-mask) or on noninvasive ventilation; and pulmonary
 infiltrates with >50% increase within 24 to 48 hours in chest-X-ray or chest CT.
 Life-threatening disease was defined as one or more of the following: respiratory
 failure on mechanical ventilation with PaO2 / FiO2 less than 300 mm Hg, septic shock,
 and/or multiple organ dysfunction.

 -  10 days from the onset of symptoms or ≤ 7 days on mechanical ventilation. -

 Exclusion Criteria:

 -  More than 10 days from symptoms onset or more than 7 days on mechanical ventilation

 -  Pregnancy

 -  Contraindication for plasma infusion because anaphylaxis history

 -  Patients with high risk of circulatory overload

 -  Limitation of therapeutic efforts

 -  Refractory shock define by norepinephrine dose more than 1 ug/k/min

 -  SOFA score more than 15 points at the moment of the protocol inclusion i Coagulopathy
 with requirements of plasma infusion